carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper-02']
#asco22 statistical plan for skyscraper-02 with 0.001 alpha to pfs, heavily weighted to os in primary analysis set (those without brain mets). about 19% had brain metastases, 11-13% were untreated. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him